The ESC 2019 CCS guidelines: Have we left our patients and scientific evidence behind?

Area of Science:

• Cardiology
• Pharmacology

Background:

• The European Society of Cardiology (ESC) and the Canadian Cardiovascular Society (CCS) 2019 guidelines acknowledge the need for individualized anginal symptom management.
• However, these guidelines offer limited specific guidance on utilizing pharmacotherapy effectively to achieve treatment goals.

Purpose of the Study:

• To summarize and discuss key points of disagreement regarding pharmacotherapy in the management of anginal symptoms.
• To provide clarity and actionable insights beyond current guideline recommendations.

Main Methods:

• Literature review of existing guidelines and relevant studies.
• Critical analysis and synthesis of differing viewpoints on anti-anginal pharmacotherapy.

Main Results:

• Identification of specific areas where current guidelines lack clarity on pharmacotherapy.
• Discussion of alternative or debated approaches to drug selection and titration for angina.

Conclusions:

• There is a need for more detailed recommendations on pharmacotherapy for anginal symptom control.
• Further research and expert consensus are required to refine treatment strategies and improve patient outcomes.